Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2015-09-30
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Several studies have shown that IPS\> 0.8 allowed a high compression, between 30 and 40 mmHg. In the case of mixed ulcers with IPS between 0.6 and 0.8, the HAS recommends using a lighter compression, bit by elastic bands (exercising low power compression at rest) under medical supervision, informing the patient to remove the bandage if pain or aggravation. It is therefore necessary to adapt the compression therapy in case of venous ulcers associated with arterial disease by providing a lower compression 30 mmHg short stretch. For HAS, IPS \<0.6 against indicates compression.
A recent study showed that compression bit elastic bands could not only improve venous return, but it would also increase the distal arterial flow in a patient population with mixed ulcers. In this study, 25 patients had between IPS 0.5 and 0.8; or for certain patients below the threshold of 0.6 indicates that against a compression according to HAS. To our knowledge this is the only study that has examined the effect of compression on blood perfusion.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Venotrain UlcerteC Venous Compression Device in the Treatment of Venous Ulcers in Daily Practice
NCT03736941
Negative Pressure Vs. Compression in Venous Ulcers
NCT03688841
Compliance of Compression Therapy in Healed Venous Ulcerations
NCT01680809
Compression Therapy Following Truncal Vein Endothermal Ablation And Distal Sclerotherapy
NCT02890563
Standard Compression Therapy With/Without Application of Skin Allograft (Theraskin) for Venous Leg Ulcer Treatment
NCT03935386
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Principal: Study the distal arterial infusion in a patient population with mixed ulcers under compression leg with little elastic bands
* Secondary: To evaluate the safety of the little compression elastic band in a mixed population of patients with leg ulcers
Methodology :
* Study non-interventional prospective single-center that evaluates professional practice from 25 patients with mixed leg ulcers and followed in the vascular medicine department of St. Joseph Hospital Group Paris.
* Applying a bit compression elastic bandages to a pressure level between 30 and 40mmHg.
* Anonymous data reports on the grid standardized collection, by a numbering system from 1 to 30 and then captured on a computer file
* Age, risk factors and cardiovascular history of the patients,
* Age, ulcer description
* Palpation of pulse
* morphological vascular profile of patients with arterial and venous Doppler dating less than a year,
* Series following data before installation, 10 minutes after application and 24 hours after installation of the inelastic compression:
o Evaluation of tolerance:
* measurement of pain numeric scale (NS)
* description of the skin condition of the leg by a dermatologist, seeking signs of suffering skin after application of compression: possible appearance of erythema, cyanosis, purpura. A search particularly in areas of bony prominences and the banks of the ulcer.
o distal arterial pressures of the compression carrier leg:
* IPS (systolic pressure index): ankle and arm pressures will be measured with a cuff and a continuous Doppler. GPI is calculated by dividing the lowest pressure at the ankle (at the dorsalis pedis or posterior tibial artery) by the humeral pressure.
* Transcutaneous Oxygen Pressure (TcPO2) o Measuring pressure exerted by low elastic bandages by Kikuhime® system.
In case of bad tolerance of compression at any time after installation, the compression will be removed and the study stopped for the patient in question. Poor tolerance is defined by an increase in pain than or equal to 2 points on the digital scale.
expected benefits for patients:
* Demonstration of good tolerance, defined as no worsening of the skin condition and the lack of increase in pain associated with inelastic compression.
* Demonstration of no worsening of arterial infusion by inelastic compression.
* Evidence of improved distal arterial hemodynamics (increased IPS and tcpO2) with a little elastic compression, which validate the results of the only study ever conducted on the subject.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A big toe pressure index (IPGO) \<0.7, with a systolic pressure of the big toe (PGO)\> 50 mmHg
Exclusion Criteria
* A normal IPS that is to say between 0.9 and 1.3, a critical ischemia (defined as ankle pressure \<70 mmHg and / or systolic pressure of the big toe \<50 mmHg)
* Presence of peripheral neuropathy,
* Presence of heart failure,
* Refusal to participate in the study or to sign the consent,
* Impaired cognitive function not to participate in a clinical study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Hôpital Saint-Joseph
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
STANSAL Audrey, MD
Role: PRINCIPAL_INVESTIGATOR
Groupe Hospitalier Paris Saint-Joseph (FRANCE)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupe Hospitalier Paris Saint Joseph
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ULCERE MIXTE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.